Guizhou Bailing Group Pharmaceutical Co Ltd Tangible Net Worth Ratio

Latest as of March 2026: 86.7%

Guizhou Bailing Group Pharmaceutical Co Ltd tangible net worth ratio. Guizhou Bailing Group Pharmaceutical Co Ltd (002424) has a Tangible Net Worth Ratio of 86.7% as of March 2026. This metric is calculated by deducting intangible assets (CN¥425.29 Million) from net assets (CN¥3.20 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Check Guizhou Bailing Group Pharmaceutical Co strategic capital allocation to assess the company's strategic physical and investment asset allocation.

Tangible NW Ratio

86.7%
Tangible equity / total equity

Net Assets (Equity)

CN¥3.20 Billion
CNY

Intangible Assets

CN¥425.29 Million
Goodwill, patents, brand value

Total Assets

CN¥5.95 Billion
CNY

Tangible Net Worth Ratio of Guizhou Bailing Group Pharmaceutical Co Ltd (2007–2025)

Tangible net worth ratio of Guizhou Bailing Group Pharmaceutical Co Ltd from 2007 to 2025. This chart shows how Guizhou Bailing Group Pharmaceutical Co Ltd's Tangible Net Worth Ratio has changed across 19 annual periods from 2007 to 2025. As of March 2026, the ratio stands at 86.7%, reflecting net assets of CN¥3.20 Billion with intangible assets of CN¥425.29 Million CNY. See Guizhou Bailing Group Pharmaceutical Co current assets vs equity to evaluate short-term liquidity relative to the company's equity base.

Guizhou Bailing Group Pharmaceutical Co Ltd Tangible Net Worth Ratio by Year (2007–2025)

Guizhou Bailing Group Pharmaceutical Co Ltd tangible net worth ratio by year from 2007 to 2025. The table below presents the year-by-year Tangible Net Worth Ratio for Guizhou Bailing Group Pharmaceutical Co Ltd from 2007 to 2025, covering 19 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see Guizhou Bailing Group Pharmaceutical Co market cap and net worth.

Year Tangible NW Ratio Net Assets (CNY) Intangible Assets Total Assets Change (pp)
2025 86.6% CN¥3.17 Billion CN¥424.14 Million CN¥6.20 Billion ▼ -0.6 pp
2024 87.2% CN¥3.20 Billion CN¥408.24 Million CN¥7.13 Billion ▼ -2.6 pp
2023 89.8% CN¥3.53 Billion CN¥358.10 Million CN¥7.35 Billion ▼ -1.9 pp
2022 91.8% CN¥4.00 Billion CN¥327.99 Million CN¥6.89 Billion ▲ +0.2 pp
2021 91.6% CN¥3.96 Billion CN¥334.01 Million CN¥6.49 Billion ▼ -2.2 pp
2020 93.8% CN¥3.92 Billion CN¥244.03 Million CN¥7.03 Billion ▲ +1.5 pp
2019 92.3% CN¥4.14 Billion CN¥319.61 Million CN¥7.05 Billion ▼ -0.8 pp
2018 93.1% CN¥3.92 Billion CN¥271.48 Million CN¥5.98 Billion ▲ +0.7 pp
2017 92.4% CN¥3.47 Billion CN¥264.45 Million CN¥4.82 Billion ▲ +0.2 pp
2016 92.2% CN¥3.07 Billion CN¥238.50 Million CN¥4.24 Billion ▼ -0.4 pp
2015 92.6% CN¥2.68 Billion CN¥198.82 Million CN¥3.84 Billion ▲ +1.1 pp
2014 91.5% CN¥2.35 Billion CN¥199.57 Million CN¥3.57 Billion ▼ -0.9 pp
2013 92.4% CN¥2.13 Billion CN¥162.31 Million CN¥3.48 Billion ▲ +0.4 pp
2012 91.9% CN¥2.04 Billion CN¥164.86 Million CN¥3.24 Billion ▲ +0.7 pp
2011 91.3% CN¥1.94 Billion CN¥169.62 Million CN¥3.02 Billion ▼ -7.1 pp
2010 98.3% CN¥1.85 Billion CN¥31.07 Million CN¥2.80 Billion ▲ +6.5 pp
2009 91.8% CN¥374.42 Million CN¥30.73 Million CN¥819.90 Million ▲ +2.8 pp
2008 89.0% CN¥262.75 Million CN¥28.97 Million CN¥583.47 Million ▲ +4.8 pp
2007 84.2% CN¥182.68 Million CN¥28.94 Million CN¥498.55 Million —
pp = percentage points